Holen Sie sich die Stockscreener-App
15.48
3.54%
-0.5675
Schlusskurs vom Vortag:
$16.05
Offen:
$16.27
24-Stunden-Volumen:
1.96M
Relative Volume:
0.71
Marktkapitalisierung:
$2.33B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-647.68M
KGV:
-2.7306
EPS:
-5.67
Netto-Cashflow:
$-594.49M
1W Leistung:
+4.04%
1M Leistung:
+43.35%
6M Leistung:
+31.87%
1J Leistung:
+12.27%
1-Tages-Spanne:
$15.05
$16.44
1-Wochen-Bereich:
$14.59
$16.50
52-Wochen-Spanne:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Firmenname
Biohaven Ltd
Sektor
Branche
Telefon
203-404-0410
Adresse
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
15.48 | 2.40B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
524.06 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.88 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.67 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.30 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.28 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-02-06 | Eingeleitet | Goldman | Buy |
| 2026-01-21 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Herabstufung | UBS | Buy → Neutral |
| 2025-11-06 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-09-16 | Eingeleitet | Jefferies | Buy |
| 2024-09-04 | Eingeleitet | Bernstein | Outperform |
| 2024-07-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2023-12-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-01-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-04 | Eingeleitet | JP Morgan | Overweight |
| 2022-12-02 | Eingeleitet | BTIG Research | Buy |
| 2022-10-26 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-05-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Herabstufung | UBS | Buy → Neutral |
| 2021-08-03 | Bestätigt | Canaccord Genuity | Buy |
| 2021-03-11 | Eingeleitet | UBS | Buy |
| 2020-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-17 | Eingeleitet | Cowen | Outperform |
| 2020-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Outperform |
| 2019-06-25 | Bestätigt | Canaccord Genuity | Buy |
| 2019-05-06 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Bestätigt | Needham | Buy |
| 2018-07-03 | Bestätigt | Needham | Buy |
| 2018-07-02 | Bestätigt | Needham | Buy |
| 2018-04-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Bestätigt | Canaccord Genuity | Buy |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-03 | Bestätigt | Needham | Buy |
Alle ansehen
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
Why Wall Street Is Growing More Cautious on Biohaven (BHVN) - Yahoo Finance
BHVNBiohaven Ltd Latest SEC Filings - Finviz
Biohaven Shares Drop 9.8% to $14.28 - Intellectia AI
Biohaven (BHVN) Insider Trading Activity 2026 - MarketBeat
Does Advancing Opakalim and BHV-1300 to Pivotal Trials Change The Bull Case For Biohaven (BHVN)? - simplywall.st
Biohaven completes enrollment in opakalim epilepsy trial - Investing.com
Biohaven completes enrollment in opakalim epilepsy trial By Investing.com - Investing.com Nigeria
Biohaven completes enrollment in focal epilepsy drug trial - StreetInsider
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator - PR Newswire
Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at BofA - Moomoo
What's Going On With Biohaven Stock Monday?Biohaven (NYSE:BHVN) - Benzinga
Biohaven (BHVN) Shares Decline Nearly 10% Amid Market Fluctuatio - GuruFocus
BHVN Downgraded by B of A Securities -- Price Target Lowered to $11 - GuruFocus
Biohaven begins phase 3 trial of BHV-1300 for Graves’ disease - Investing.com
BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - marketscreener.com
Biohaven Doses First Patient in Phase 3 Trial of BHV-1300 for Graves' Disease - marketscreener.com
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
Update: BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - Moomoo
BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target - Moomoo
BofA downgrades Biohaven stock on epilepsy drug concerns By Investing.com - Investing.com Australia
BofA Securities Downgrades Biohaven(BHVN.US) to Sell Rating, Cuts Target Price to $11 - Moomoo
BofA downgrades Biohaven stock on epilepsy drug concerns - Investing.com
Biohaven's BHV-1300 targets the root cause of Graves' disease in Phase 3 - Stock Titan
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease - Sahm
BHVN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
BHVN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
BHVN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Deutsche Bank Adjusts Biohaven Price Target to $20 From $15, Maintains Buy Rating - Moomoo
Biohaven Ltd (BHVN) Stock Price, Quote, News & History - Benzinga
Deutsche Bank Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
Biohaven Ltd. Actuals & Estimates (NYSE:BHVN) - TradingView
ZH6 Forecast — Price Target — Prediction for 2027 - TradingView
BHVN Forecast — Price Target — Prediction for 2027 - TradingView
Biohaven's Troriluzole Could Drive Potential Upside if the Company Overcomes Regulatory Hurdles, RBC Says - marketscreener.com
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Raymond James Maintains Biohaven(BHVN.US) With Buy Rating - Moomoo
Biohaven (BHVN) Is Up 22.2% After Advancing Multiple Immunology And Oncology Candidates To Pivotal Trials - Sahm
Behavioral Patterns of BHVN and Institutional Flows - Stock Traders Daily
Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials - Insider Monkey
Could Biohaven’s Expanding Pipeline Boost Russell 1000 Momentum? - Kalkine Media
Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares - simplywall.st
Biohaven Ltd (BHVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biohaven Ltd (BHVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biohaven Ltd (BHVN) Institutional Confidence - TradingKey
Biohaven Ltd (BHVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biohaven Ltd. (BHVN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
BIOHAVEN LTD (BHVN) Stock Chart - ChartMill
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations - Seeking Alpha
CCORF Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Finanzdaten der Biohaven Ltd-Aktie (BHVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biohaven Ltd-Aktie (BHVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Buten Matthew | Chief Financial Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
4,250 |
0 |
198,246 |
| Coric Vlad | Chief Executive Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
14,250 |
0 |
1,811,398 |
| Car Bruce | Chief Scientific Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
4,750 |
0 |
10,096 |
| Clark George C. | VP, Chief Accounting Officer |
Jan 05 '26 |
Option Exercise |
0.00 |
2,500 |
0 |
68,095 |
| Clark George C. | VP, Chief Accounting Officer |
Nov 17 '25 |
Buy |
8.52 |
17,000 |
144,770 |
20,000 |
| Bailey Gregory | Director |
Nov 13 '25 |
Buy |
7.50 |
400,000 |
3,000,000 |
2,020,071 |
| CHILDS JOHN W | Director |
Nov 13 '25 |
Buy |
7.50 |
3,333,333 |
24,999,998 |
5,653,904 |
| Coric Vlad | Chief Executive Officer |
Nov 13 '25 |
Buy |
7.50 |
666,666 |
4,999,995 |
1,195,275 |
2.18%
2.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):